NCT00472693View on ClinicalTrials.gov

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Breast Cancer
Interventions
DRUG

Bevacizumab, Abraxane

Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.

Trial Locations (1)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER